Form 4: Corcept CFO Mokari Buys Shares, Manages Vesting

Corcept Therapeutics CFO Atabak Mokari reported acquiring company shares through a purchase plan and managing tax obligations related to restricted stock unit vesting.

Summary

• Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc. (CORT), reported transactions involving the company's common stock.
• On December 1, 2025, Mokari purchased 178 shares of common stock at $79.78 per share through a purchase plan established under the 2024 Incentive Award Plan.
• Also on December 1, 2025, Mokari acquired 178 shares of unvested restricted stock awards under the same Purchase Plan, with a price of $0.00.
• On December 2, 2025, 118 shares were disposed of at $79.78 per share to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• Following these transactions, Mokari beneficially owns 14,559 shares of common stock directly.
• The beneficial ownership includes 232 shares from a March 3, 2025 grant, 775 shares from a June 2, 2025 grant, and 200 shares from a September 2, 2025 grant, all underlying unvested restricted stock awards that vest on their one-year anniversary.
• The 178 unvested restricted stock awards acquired on December 1, 2025, will vest on their one-year anniversary, provided Mokari remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Sentiment

Score: 6

Explanation: The filing indicates routine insider transactions, including a purchase by the CFO and the vesting of restricted stock awards. While the purchase is a positive signal of insider confidence, the overall impact is neutral as it's part of a pre-established plan and includes tax-related selling.

Positives

• CFO Atabak Mokari acquired 178 shares of common stock through a company purchase plan, indicating continued investment in the company.
• Mokari also received 178 shares of unvested restricted stock awards, aligning executive incentives with long-term shareholder value.
• The vesting of restricted stock units implies the achievement of prior performance or service conditions.

Negatives

• 118 shares were disposed of to cover tax withholding obligations, which is a common practice but represents a reduction in direct ownership.

Risks

• The vesting of certain restricted stock awards is contingent upon the Reporting Person satisfying specific requirements or remaining the beneficial owner of Purchase Plan Shares through the one-year anniversary of the grant date. Failure to meet these conditions could result in forfeiture.

Future Outlook

The vesting of restricted stock awards is tied to future dates (one-year anniversary of grant dates) and continued satisfaction of certain requirements, including remaining the beneficial owner of Purchase Plan Shares for some awards.

Industry Context

This filing reflects routine insider equity transactions and compensation practices common across publicly traded companies, particularly in the biotechnology or pharmaceutical sector where Corcept Therapeutics operates. Executive compensation often includes equity components like restricted stock awards and purchase plans to align management interests with long-term company performance.

Comparison to Industry Standards

• The use of restricted stock awards and employee stock purchase plans is a standard practice in executive compensation across various industries, including pharmaceuticals.
• The disposition of shares for tax withholding is a common and expected event when equity awards vest, aligning with standard tax regulations for non-cash compensation.
• The structure of vesting over a one-year period is a common retention mechanism.

Related Party Transactions

• The transactions involve the Chief Financial Officer acquiring and disposing of company stock, which are by definition related party transactions (insider transactions).

Stakeholder Impact

• Shareholders: The CFO's purchase of shares through a plan could be seen as a positive signal of management's belief in the company's future. The vesting of restricted stock awards aligns management's interests with shareholder value.
• Employees: The existence of an Incentive Award Plan and Purchase Plan suggests a structured approach to employee and executive compensation, which can be a positive for retention and motivation.

Next Steps

• The remaining unvested restricted stock awards will vest on their respective one-year anniversaries, subject to the reporting person satisfying certain requirements.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including a planned stock purchase and tax-related share disposition. While the CFO's purchase through a plan is a minor positive signal of confidence, it does not represent a significant change in the company's fundamental outlook or financial performance. The transactions are largely administrative and expected for an executive receiving equity compensation. Therefore, it does not warrant a change in investment stance based solely on this filing.

Keywords

Corcept Therapeutics, CORT, Atabak Mokari, CFO, Form 4, insider transaction, stock purchase, restricted stock, equity compensation, tax withholding, beneficial ownership